Rami Manochakian/X
Jun 3, 2025, 09:48
Rami Manochakian: Results of ALNEO Phase 2 Trial at ASCO25
Rami Manochakian, Vice President of the North American Neuroendocrine Tumor Society, posted on X:
“Hot Off The Press, Just presented at ASCO25.
Results of ALNEO phase 2 trial of: Neoadjuvant and Alectinib in potentially resectable stage Ill ALK+ Non-Small Cell Lung Cancer
- pCR: 12%
- MPR: 46%
- ORR: 67%
- Safety profile consistent with previous studies.”
See also:
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 2, 2025, 20:50
Sep 2, 2025, 18:53
Sep 2, 2025, 16:54
Sep 2, 2025, 16:41